PDCD1 and urinary bladder cancer: Newer advances in immunotherapy for bladder cancer have mainly focused on immune checkpoint inhibitors, particularly programmed death ligand 1 (PD-L1), programmed cell death protein 1 (PD-1) inhibitors.